Featured Research

from universities, journals, and other organizations

Little Evidence Behind Bronchodilator Therapy For Cystic Fibrosis

Date:
October 26, 2005
Source:
Center for the Advancement of Health
Summary:
Little evidence exists to support the widespread use of bronchodilators to treat children and adults with cystic fibrosis, according to a new systematic review of published research.

Little evidence exists to support the widespread use of bronchodilators to treat children and adults with cystic fibrosis, according to a new systematic review of published research.

“Recurrent wheeze and breathlessness are common in people with cystic fibrosis, and bronchodilators are commonly prescribed,” according to lead author Clare Halfhide, M.D., of the Royal Liverpool Children’s Hospital in England. “Despite their wide-scale and often long-term use, there is limited objective evidence about their efficacy in cystic fibrosis.”

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Cystic fibrosis is a genetically inherited disease afflicting the lungs and the digestive system, the result of both parents passing on an abnormal gene. It is chronic, progressive and ultimately fatal.

Cystic fibrosis causes the exocrine glands, which produce sweat and mucus, to produce thick mucus that clogs the lungs, causing chronic respiratory difficulties. The mucus also obstructs pancreatic ducts, preventing digestive enzymes from reaching the intestines. Consequently, people with cystic fibrosis have difficulties breathing, absorbing nutrients and eliminating non-digested food.

The Cochrane review included 14 trials randomized controlled trials comprising 257 participants with cystic fibrosis.

Several trials compared inhaled bronchodilator drugs to placebo by looking at two common measures of lung function. Forced expiratory volume, or FEV1, represents the volume of air that can be forced out in one second after taking a deep breath. Peak expiratory flow rate represents how fast a person can exhale air.

Improvements occurred primarily in a subgroup of the cystic fibrosis patients studied. These patients were known to have bronchial hyper-responsiveness — increased response of the airway to certain stimuli. Bronchial hyper-responsiveness and responsiveness to bronchodilator drugs are markers for asthma and can be also tested for in people with cystic fibrosis.

The reviewers found the following:

--Albuterol and terbutaline — drugs classified as short-acting beta2-agonists — increased FEV1 and peak expiratory flow rate for patients known to have bronchial hyper-responsiveness.

--Serevent (salmeterol) — classified as a long-acting beta2-agonist — also improved lung function for participants known to have bronchial hyper-responsiveness.

--Atrovent (ipratropium bromide) showed no consistent effects on lung function in the trials under review.

The reviewers found no published trials that included inhaler-delivered fenoterol, formoterol or tiotropium and wrote that use of those agents could not be supported.

The reviewers noted that the trials were too varied in design to allow for a pooling of data for a strict meta-analysis.

“[B]efore embarking on what might become lifelong bronchodilator therapy, bronchodilator responsiveness should be assessed by measuring lung function both before and after a test dose of salbutamol in a standardized way, looking for an increase in baseline FEV1 of at least 10 percent," the reviewers concluded.

John Colombo, M.D., professor and chief of the pediatric pulmonology section at the University of Nebraska Medical Center, said, “My bias is… that all CF [cystic fibrosis] patients deserve a trial of beta-agonist bronchodilator. This should be done in the PFT [pulmonary function test] laboratory, and, unless they develop significant adverse effects, short-acting beta-agonists should be considered as a trial for symptom relief, and possibly as an adjunct to airway clearance. A long-acting beta-agonist, of which salmeterol is the only one studied to date, should be considered for a period of home use with assessment for changes in symptoms, antibiotic requirement, and PFT course.”

About 30,000 people in the United States are affected with cystic fibrosis, and 2,500 to 3,000 babies are born annually with the condition. It most commonly occurs in Caucasians of Northern European heredity.


Story Source:

The above story is based on materials provided by Center for the Advancement of Health. Note: Materials may be edited for content and length.


Cite This Page:

Center for the Advancement of Health. "Little Evidence Behind Bronchodilator Therapy For Cystic Fibrosis." ScienceDaily. ScienceDaily, 26 October 2005. <www.sciencedaily.com/releases/2005/10/051026085739.htm>.
Center for the Advancement of Health. (2005, October 26). Little Evidence Behind Bronchodilator Therapy For Cystic Fibrosis. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/10/051026085739.htm
Center for the Advancement of Health. "Little Evidence Behind Bronchodilator Therapy For Cystic Fibrosis." ScienceDaily. www.sciencedaily.com/releases/2005/10/051026085739.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins